

## Jenburkt Pharmaceuticals Ltd.

Regd. Office: 93, J. P. Road, Andheri (West), Mumbai - 400 058. • Phone: 67 603 603 • Fax: 91-22-6694 3127 Email : info@jenburkt.com • www.jenburkt.com • CIN No. L24230MH1985PLCO36541

PAR	П				(Rs. In Lacs)
Α	В	С	D	Е	F
Sr.	Particulars	Quarter ended			Year ended
No.		30/06/2015	31/03/2015	30/06/2014	31/03/2015
		Unaudited	Audited	Unaudited	Audited
1	Income from Operations				
	a) Net Sales/Income from Operations (Net of Excise Duty)	2184.31	2224.55	1920.93	8501.80
	b) Other Operating Income	37.74	11.26	1.72	19.24
	Total Income from Operations (Net)	2222.05	2235.81	1922.65	8521.04
2	Expenses				
	a) Cost of Materials Consumed	173.95	662.98	209.69	2657.02
	b) Purchases of Stock in Trade	484.46	0.25	336.55	1.40
	c) Changes in Inventories of Finished Goods, Work-in-progress and Stock-	10 11 10	5,22		=:
	in-Trade	8.29	17.82	28.11	-65.26
	d) Employee benefits Expense	548.99	467.63	488.95	1899.32
	e) Depriciation and amortisation Expense	45.75	77.56	37.50	265.90
	f) Other Expenses	645.37	684.69	608.00	2503.24
	Total Expenses	1906.81	1910.93	1708.80	7261.6
	Profit / (Loss) from Operations before other income, finance cost and	1500.01	1510.55	2700.00	720210
3	exceptional items (1-2)	315.24	324.88	213.85	1259.47
4	Other Income	58.90	158.19	6.34	207.24
4		36.30	130.13	0.34	207.2
5	Profit / (Loss) from Ordinary activities before finance costs and	274.14	483.07	220.19	1466.66
	exceptional items (3+4)	<b>374.14</b> 10.39	9.24	11.53	35.65
6	Finance Cost	10.39	9.24	11.53	33.03
7	Profit / (Loss) from ordinary activities after finance cost but before	262.75	472.02	200.00	1421 0
	exceptional items (5-6)	363.75	473.83	208.66	1431.03
8	Exceptional Items	0.00	2.82	0.16	2.98
9	Profit / (Losss) from Ordinary activities before tax (7+8)	363.75	476.65	208.82	1433.9
10	Tax Expense	100.15	200.50	60.00	
	Direct Tax	100.15	209.50	60.00	512.5
See Producti	Deffered Tax	8.25	43.35	0.00	-43.4
11	Net Profit / (Loss) from Ordinary activities after tax (9-10)	255.35	223.80	148.82	964.9
	Extra ordinary items	0.00	0.00	0.00	0.0
13	Net Profit / (Loss) for the period (11+12)	255.35	223.80	148.82	964.9
14	Share of Profit / (Loss of Associates)	0.00	0.00	0.00	0.0
15	Minority Interest	0.00	0.00	0.00	0.0
16	Net Profit / (Loss) after taxes, minority interest and share of profit/(loss) of Associates (13+14+15)	255.35	223.80	148.82	964.9
47		464.93	464.93	464.93	464.9
17	Paid-up equity share capital (Face Value of Rs. 10/- each)		404.93	404.33	404,3
18	Reserve excluding Revaluation Reserves (as per balance sheet of previous accounting year)	i i	lù.	B	2878.9
19 i	Earnings Per Share (EPS) (before extraordinary items) (of Face Value of				
	Rs. 10/- each) (not annualised)				
	(a) Basic	5.49	4.81	3.20	20.7
	(b) Diluted	5.49	4.81	3.20	20.7
19 ii	Earnings Per Share (EPS) (after extraordinary items) (of Face Value of Rs.	5.10			
	10/- each - not annuallised)				
	(a) Basic	5.49	4.81	3.20	20.7
	(b) Diluted	5.49	4.81	3.20	20.7





## Jenburkt Pharmaceuticals Ltd.

Regd. Office: 93, J. P. Road, Andheri (West), Mumbai - 400 058. • Phone: 67 603 603 • Fax: 91-22-6694 3127 Email : info@jenburkt.com • www.jenburkt.com • CIN No. L24230MH1985PLCO36541

C1	Particulars	Quarter ended			Year ended			
Sr. No.		30.06.2015 Unaudited	31.03.2015 Audited	30.06.2014 Unaudited	31/03/2015 Audited			
10.								
A.	Particulars of Shareholding				3444			
1	Public shareholding			1				
	- Number of shares	2513833	2494513	2466923	249451			
	- Percentage of shareholding	54.07	53.65	53.06	53.6			
2	Promoters and Promoter Group Shareholding							
	a) Pledged / Encumbered							
	- Number of shares	0	0	0				
	<ul> <li>Percentage of shares (as a % of the total shareholding of promoter and promoter group)</li> </ul>	0	0	0				
	<ul> <li>Percentage of shares (as a % of the total share capital of the company)</li> </ul>							
	b) Non - encumbered							
	- Number of shares	2135467	2154787	2182377	215478			
	<ul> <li>Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)</li> </ul>	100.00	100.00	100.00	100.0			
	<ul> <li>Percentage of shares (as a % of the total share capital of the company)</li> </ul>	45.93	46.35	46.94	46.3			
	Particulars	30/06/2015		THE RESERVE OF THE PARTY OF THE				
	INVESTOR COMPLAINTS							
	Pending at the beginning of the quarter	Nil						
	Received during the quarter	9						
91	Disposed of during the quarter	9						
-	Remaining unresolved at the end of the quarter	Nil						
	Notes:			V				
	1. The above unaudited results were reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their respective meetings held on 24.07.2015							
	The Limited Review of the above results has been carried out by the Statutory Auditors.							
	3. The Company is dealing exclusively in pharmaceuticals business segme	is not applicable						
	4. Figures of previous quarter/year are regrouped/ rearranged, wherever no		anewise reporting	, is not applicable				
				By order of the Board				
	Place : Mumbai		For Jenburkt Pharmaceuticals Ltd.					
	Date: 24/07/2015		Alist the Blot					